Positive Response to Thermobalancing Therapy Enabled by Therapeutic Device in Men with Non-Malignant Prostate Diseases: BPH and Chronic Prostatitis

Ivan Aghajanyan,Simon Allen

doi:10.3390/diseases4020018

Abstract

Background: The most common types of non-malignant prostate diseases are benign prostatic hyperplasia (BPH) and chronic prostatitis (CP). The aim of this study was to find out whether thermobalancing therapy with a physiotherapeutic device is effective for BPH and CP. Methods: During a 2.5-year period, 124 men with BPH over the age of 55 were investigated. Clinical parameters were tested twice: via the International Prostate Symptom Score (IPSS) and via ultrasound measurement of prostate volume (PV) and uroflowmetry maximum flow rate (Qmax), before and after six months of therapy. In 45 men with CP under the age of 55, the dynamics of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) were studied. Results: The results of the investigated index tests in men with BPH confirmed a decrease in IPSS (p < 0.001), a reduction in PV (p < 0.001), an increase in Qmax (p < 0.001), and an improvement of quality of life (QoL) (p < 0.001). NIH-CPSI scores in men with CP indicated positive dynamics. Conclusions: The observed positive changes in IPSS, PV, and Qmax in men with BPH and the improvement in NIH-CPSI-QoL in patients with CP after using a physiotherapeutic device for six months as mono-therapy, support the view that thermobalancing therapy with the device can be recommended for these patients. Furthermore, the therapeutic device is free of side effects.

Highlights

The prevalence of histologically diagnosed prostatic hyperplasia increases from 8 percent in men aged 31–40, to 40–50 percent in men aged 51–60, and to over 80 percent in men older than age 80 [1].Epidemiologic data suggest that the prevalence of chronic prostatitis (CP) is comparable to ischemic heart disease and diabetes mellitus, as about 8.2% men are believed to be affected [2]
Benign prostate hyperplasia (BPH) and CP are common diseases in males, and benign prostate hyperplasia (BPH) is often complicated by CP [3]
Effectiveness of the therapeutic device was studied by comparing men with BPH, who received treatment with the therapeutic device, with a control group in the watchful waiting stage, and by comparing patients with CP who received treatment with the therapeutic device with the control no-treatment group

Summary

Introduction

Epidemiologic data suggest that the prevalence of chronic prostatitis (CP) is comparable to ischemic heart disease and diabetes mellitus, as about 8.2% men are believed to be affected [2]. Benign prostate hyperplasia (BPH) and CP are common diseases in males, and BPH is often complicated by CP [3]. Chronic inflammation in the prostate gland plays an important role in the development of BPH [4]. Inflammation may be considered a key component of BPH pathogenesis, in addition to androgen receptor signaling in tissue remodeling typical of the advanced stages of the disease [5]. Accumulating evidence suggests that inflammation may contribute to the development of BPH and LUTS. The most common types of non-malignant prostate diseases are benign prostatic hyperplasia (BPH) and chronic prostatitis (CP).

Objectives

Methods

Conclusion